The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...

Please provide your email address to receive an email when new articles are posted on . IL-13, which dupilumab blocks, induces nitric oxide production, which leads to mucus hypersecretion. At week 24, ...

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab. A study on the efficacy of the biologic drug, dupilumab, found ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is the first drug approved for treating children with eosinophilic esophagitis. The safety profile in ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

VANCOUVER, Canada — New evidence from the phase 3 EoE KIDS trial supports the safety and efficacy of dupilumab (Dupixent) treatment for children aged 1-11 years with eosinophilic esophagitis (EoE).

CHMP recommends approval of Dupixent ® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis PARIS and TARRYTOWN, NY – September 20, 2019 – The European Medicines Agency’s Committee for ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

The Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) for the treatment of chronic spontaneous ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...